do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance Role of in Clinical Practice DPP-4 inhibitors and GLP-1RAs: cardiovascular
Description
Metabolic bariatric surgery is the most effective treatment for durable weight loss and improvement of obesity-related conditions but is invasive and vastly underutilized
May have higher risk of GI or metabolic side effects
Anti-exenatide antibodies were detected in 40%-60% of clinical patients
This increased cAMP activates PKA which in turn promotes insulin synthesis and secretion and inhibits glucagon release (Yang and Yang, 2016)
GLP-1 is also involved in multiple other physiological processes including appetite, cardiovascular function, and inflammation (1)
